Jordi Bertran-Alamillo

Jordi Bertran-Alamillo

UNVERIFIED PROFILE

Are you Jordi Bertran-Alamillo?   Register this Author

Register author
Jordi Bertran-Alamillo

Jordi Bertran-Alamillo

Publications by authors named "Jordi Bertran-Alamillo"

Are you Jordi Bertran-Alamillo?   Register this Author

22Publications

894Reads

6Profile Views

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients.

Expert Rev Respir Med 2019 Oct 19;13(10):1019-1028. Epub 2019 Aug 19.

Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2019.1656068DOI Listing
October 2019

Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.

J Thorac Oncol 2018 09 8;13(9):1324-1337. Epub 2018 May 8.

Instituto Oncológico Dr. Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Catalan Institute of Oncology and Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.04.030DOI Listing
September 2018

Liquid Biopsy in Non-Small Cell Lung Cancer.

Front Med (Lausanne) 2016 23;3:69. Epub 2016 Dec 23.

Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2016.00069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179978PMC
December 2016

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.

Melanoma Res 2015 Dec;25(6):486-95

aTranslational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital bPangaea Biotech S.L cHospital Vall d'Hebron dCatalan Institute of Oncology, Hospital Germans Trias i Pujol Badalona eMORe Foundation, Barcelona fHospital Central Asturias, Oviedo gPivotal SL, Madrid hCUN, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000187DOI Listing
December 2015

cfDNA analysis from blood in melanoma.

Ann Transl Med 2015 Nov;3(20):309

1 Laboratory of Oncology/Pangaea Biotech S.L, Hospital Quiron Dexeus, Barcelona, Spain ; 2 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 3 Catalan Institute of Oncology, Hospital Germans Trias i Pujol Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.11.23DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669327PMC
November 2015

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

Clin Cancer Res 2014 Apr 3;20(7):2001-10. Epub 2014 Feb 3.

Authors' Affiliations: Pangaea Biotech, Barcelona, Spain; Hospital Sant Pau, Barcelona, Spain; Hospital Vall d'Hebron, Barcelona, Spain; Molecular Oncology Research (MORe) Foundation, Barcelona, Spain; Pivotal, Madrid; Hospital General de Alicante, Alicante, Spain; Catalan Institute of Oncology, Badalona, Barcelona, Spain; Complejo Hospitalario Universitario, La Coruña, Spain; Centre François Baclesse, Caen, France; Drum Tower Hospital, Nanjing, China; Kyushu University, Fukuoka, Japan; Cancer Therapeutics Innovation Group, New York, New York, USA; and Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2233DOI Listing
April 2014

CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors.

Transl Lung Cancer Res 2013 Apr;2(2):65-71

Breakthrought Cancer Unit, Laboratory of Oncology, Pangaea Biotech, Dexeus University Hospital, Barcelona, Spain ; ; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://www.tlcr.org/article/view/1027
Publisher Site
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.02.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369853PMC
April 2013

Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.

Pharmacogenomics 2012 May;13(7):789-802

Pangaea Biotech, Laboratory of Oncology, USP Dexeus University Institute, Sabino Arana, 5-19, 08028 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.12.54DOI Listing
May 2012

Screening for EGFR mutations in lung cancer.

Discov Med 2009 Dec;8(43):181-4

Medical Oncology Service, Pangaea Biotech, USP Institut Universitari Dexeus, Barcelona, Catalunya, Spain.

View Article

Download full-text PDF

Source
December 2009

IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors.

Future Oncol 2009 Apr;5(3):305-8

Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain and, Pangaea Biotech, USP Instituto Universitario Dexeus, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.09.3DOI Listing
April 2009